Loading...
•
Sep 30, 2024
Palatin Technologies Q1 2025 Earnings Report
Palatin Technologies reported results for the first quarter of fiscal year 2025.
Key Takeaways
Palatin Technologies reported a net loss of $7.8 million for the quarter ended September 30, 2024, compared to a net loss of $5.2 million for the same period in 2023. The company had no product sales due to the sale of Vyleesi's worldwide rights. The company's cash and cash equivalents were $2.4 million as of September 30, 2024.
Palatin completed patient enrollment in Phase 2 BMT-801 clinical study for obesity program.
The company is advancing obesity programs and planning multiple clinical trials in 2025.
Strategic options are being explored for non-obesity programs with significant interest from multiple parties.
Palatin is actively engaged with potential funding sources for future operating cash needs.
Forward Guidance
Palatin is focused on advancing its obesity programs and exploring strategic options for its non-obesity programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...